Pave the road to successful commercialization of your radiopharmaceutical innovation with CARI – The CPDC & adMare Radiopharmaceutical Initiative

October 6, 2020 CPDC

If you are an academic researcher or a biotech company looking to pave the road to successful commercialization of your radiopharmaceutical innovation, join us on October 15th, 2020.

What is CARI?

CARI is a collaboration between The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) where we will bring respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain considerable global competitive advantage: RADIOPHARMACEUTICALS. The objective of CARI, is for CPDC and adMare to seek out and uncover radiopharmaceutical opportunities arising from academic discoveries and early enterprises, establish rigorous drug development programs around selected opportunities, and drive the generation of proof-of-principle and other data supportive of the commercialization of new radiopharmaceutical assets.

Have more questions about CARI? Then you don’t want to miss this Webinar!

Please kindly register before Wednesday, Oct. 14th – click here to register.

More news from CPDC

Centre for Probe Development & Commercialization (CPDC) Appoints New Interim CEO

Hamilton, Ontario (October 22, 2020) ‐ Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the Company’s Board of Directors has appointed Bruno Paquin as Interim Chief Executive Officer, effective November 2, 2020. Justyna Kelly, CPDC’s outgoing CEO said, “Since joining CPDC,

Unleashing Canada’s Radiopharmaceutical Excellence. New Pan-Canadian Partnership Looks to Commercialize the Country’s Most Promising Radiopharmaceutical Innovations

The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) are pleased to announce they have formed a new collaboration, “The CPDC-adMare Radiopharmaceutical Initiative (CARI)” to bring their respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain a considerable global competitive advantage: radiopharmaceuticals. This

Isotopia Molecular Imaging and CPDC Announce Production Agreement for n.c.a. Lu-177

Hamilton, Ontario, September 8, 2020 – Isotopia Molecular Imaging and CPDC are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer, including neuroendocrine tumors and prostate cancer.

For more information contact us at: